We are monitoring the impact of COVID-19 on Gastroparesis Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 5069
Share on
Share on

Global Gastroparesis Drugs Market Size, Share, Trends, COVID-19 Impact and Growth Analysis Report – Segmented By Drug Class, Disease Type, End User and Region - Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 5069
Pages: 145

Gastroparesis Drugs Market Size (2021 to 2026)

The Global Gastroparesis Drugs market size is forecasted to be growing at a CAGR of 4.8% during the forecast period. The size of the market is predicted to be worth USD 6.92 billion by 2026 from USD 5.47 billion in 2021.

Normal spontaneous movements of the stomach muscles are affected when a person is suffering from Gastroparesis, often causing vomiting, improper digestion, etc. Erythromycin, Reglan are few drugs prescribed for the treatment.

MARKET DRIVERS:

Augmenting the geriatric population, increased number of surgeries causing Gastroparesis as a side effect, a growing number of people with diabetes, and introducing new drugs to control symptoms such as nausea are majorly driving the global gastroparesis drugs market.

Y-O-Y growth in the diabetic population, increased number of surgeries, and a rising aging population are other significant factors that successfully drive gastroparesis market growth. The hiking demand for gastroparesis drugs and the launch of novel drugs in preventing symptoms like nausea and vomiting surges the market demand.

The increase in the number of surgeries leading to post-surgical gastroparesis conditions and growing commonness of diabetic Mellitus in people, rising R&D activities by the manufacturers to produce more advanced drugs required to treat gastroparesis are further expanding the growth scope. The National Institute of Health (NIH) revealed that type I diabetes quickly affects many children and teenagers. The growing number of hospitals with well-equipped, furnished, and healthcare infrastructure and climbing healthcare expenses mount the market growth. 

MARKET RESTRAINTS:

However, adverse side-effects relevant to gastroparesis drugs may hinder the market growth. The completion of clinical trials is to limit the market demand. The absence of experienced medical professionals and lack of awareness among people regarding the early diagnosis and treatment restrain the market demand during the estimated period. 

Impact of COVID-19 on the global gastroparesis drugs market:

The COVID-19 pandemic has disrupted the supply chain management of over-the-counter (OTC) and prescription drugs impede the market growth in the next few months. The medical healthcare professionals mainly concentrate on the COVID-19 that led to less focus on the diagnosis and treatment for gastroparesis, restraining the market's growth. The COVID-19 has created an adverse effect on the gastroparesis drugs market. The first COVID-19 case reported in the United States has developed the GI symptoms like vomiting and diarrhea. It is mandatory for clinicians, extremely gastroenterologists, to be conscious of typical and rarely missed presentations of COVID-19. The unfavorable drug can be another feasible explanation. Some of the antivirals, antibiotics, and immunomodulators prescribed to COVID-19 patients cause diarrhea—the high commonness of GI symptoms reported in the studies. 

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Type, Production Technologies, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

 

This research report on the global gastroparesis drugs market has been segmented and sub-segmented based on the type, production technologies, and region.

Gastroparesis Drugs Market – By Drug Class:

  • Prokinetic Agents 
  • Antiemetic Agents
  • Botulinum Toxin Injections     

The prokinetic agent is expected to lead the global gastroparesis drugs market based on the drug class during the forecast period. The prokinetic agent is used to ease gastrointestinal symptoms like bloating, constipation, abdominal discomfort, and vomiting. Factors driving the segment are easy availability, efficacy, high-usage, and medications' applicability in treating gastroparesis.

The botulinum toxin injections segment grows with the highest CAGR growth rate and is expected to maintain its dominance during the historical period.

Gastroparesis Drugs Market – By Disease Class:

  • Diabetic Gastroparesis       
  • Idiopathic Gastroparesis    
  • Post-surgical Gastroparesis              
  • Others      

Based on disease class, the Idiopathic Gastroparesis segment performed a leading role in the market in 2019 and will retain its position till 2025. Its causes are unknown. However, this condition can be managed by dietary management. The segment growth is due to advancements in novel and efficient therapies for the diagnostic control of idiopathic gastroparesis. The rising diabetes mellitus population worldwide leads to high demand for diagnosis and treatment, and diabetes is a common cause of gastroparesis accumulating the market growth. 

The post-surgical gastroparesis segment is scheduled to thicken at a quick rate during the forecast timeline. The amplifying number of surgeries like transplantation augment the gastroparesis drugs market growth globally. 

Gastroparesis Drugs Market – By End User:

  • Hospitals  
  • Pharmacies             
  • Clinics       
  • E-commerce      

The hospital end-user segment is leading the market globally. Augmenting the number of hospitals with well-equipped infrastructure, experienced medical professionals, and a growing huge patient count escalates the segment growth during the analysis period.

The pharmacy segment is predicted to grow with the most considerable CAGR growth pace.

Gastroparesis Drugs Market – By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Regionally, North America accounted for the largest share in the global gastroparesis drugs market in 2019. The US is expected to lead the regional market in the forecast period. Europe is a close second by market share. The UK captured the largest market share in the European market.

The Asia Pacific is the fastest-growing market and is anticipated to remain so in the forecast period. Emerging economies of India and China are spearheading this growth spurt. The Asia-Pacific region exhibits gainful opportunities for many companies as India has a high standard pace of diabetes, leading to gastroparesis disorder contributing a significant share in the market. Initiatives to assist product approvals and labeling claims for diabetic gastroparesis treatments provide profitable opportunities for the market players. Vast unused market potential among the emerging countries like China and India and the advancement of novel gastroparesis drugs provide gainful opportunities to the market players. 

Latin America and MEA are poised for robust growth in the forecast period due to increased investments by major companies in the market.

KEY MARKET PARTICIPANTS:

Some of the most prominent companies dominating the Global Gastroparesis Drugs Market profiled in this report are Bayer HealthCare AG, Bioniche Animal Health Canada, Sanofi Animal Health, Inc., Biogenesis Bago SA, Heska Corporation, Indian Immunologicals Ltd., Boehringer Ingelheim GmbH, Zoetis, Novartis Animal Health, Inc., Merck & Co. Inc. and Protein Sciences.

RECENT MARKET HAPPENINGS:

  • In January 2017, Soliqua 100/33 (insulin glargine 100 Units/ml& lixisenatide 33mcg/mL injection) by Sanofi, available in the U.S pharmacies the treatment of adults with type 2 diabetes.
  • In December 2018, Vanda Pharmaceuticals, Inc. declared tradipitant met the primary endpoint VLY686-2301, a phase-II clinical study among the patients with idiopathic and diabetic gastroparesis. 

1. Introduction                                

               1.1 Market Definition                    

               1.2 Study Deliverables                  

               1.3 Base Currency, Base Year and Forecast Periods                          

               1.4 General Study Assumptions                 

2. Research Methodology                                          

               2.1 Introduction                             

               2.2 Research Phases                      

                              2.2.1 Secondary Research           

                              2.2.2 Primary Research 

                              2.2.3 Econometric Modelling      

                              2.2.4 Expert Validation  

               2.3 Analysis Design                        

               2.4 Study Timeline                         

3. Overview                                     

               3.1 Executive Summary                

               3.2 Key Inferences                         

               3.3 Epidemology                            

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

               4.1 Market Drivers                         

               4.2 Market Restraints                   

               4.3 Key Challenges                         

               4.4 Current Opportunities in the Market               

5. Market Segmentation                                            

               5.1 Drug Class                  

                              5.1.1 Introduction           

                              5.1.2 Prokinetic Agents 

                              5.1.3 Antiemetic Agents

                              5.1.4 Botulinum Toxin Injections              

                              5.1.5  Y-o-Y Growth Analysis, By Drug Class          

                              5.1.6  Market Attractiveness Analysis, By Drug Class        

                              5.1.7  Market Share Analysis, By Drug Class         

               5.2 Disease Type                            

                              5.2.1 Introduction           

                              5.2.2 Diabetic Gastroparesis       

                              5.2.3 Idiopathic Gastroparesis    

                              5.2.4 Post-surgical Gastroparesis              

                              5.2.5 Others      

                              5.2.6 Y-o-Y Growth Analysis, By Disease Type      

                              5.2.7 Market Attractiveness Analysis, By Disease Type    

                              5.2.8 Market Share Analysis, By Disease Type     

               5.3 End User                     

                              5.3.1 Introduction           

                              5.3.2 Hospitals  

                              5.3.3 Pharmacies             

                              5.3.4 Clinics       

                              5.3.5 E-commerce          

                              5.3.6 Y-o-Y Growth Analysis, By End User             

                              5.3.7 Market Attractiveness Analysis, By End User            

                              5.3.8 Market Share Analysis, By End User             

6. Geographical Analysis                                            

               6.1 Introduction                             

                              6.1.1 Regional Trends    

                              6.1.2 Impact Analysis     

                              6.1.3 Y-o-Y Growth Analysis        

                                             6.1.3.1 By Geographical Area

                                             6.1.3.2 By Drug Class

                                             6.1.3.3 By Disease Type

                                             6.1.3.4 By End User

                              6.1.4  Market Attractiveness Analysis      

                                             6.1.4.1 By Geographical Area

                                             6.1.4.2 By Drug Class

                                             6.1.4.3 By Disease Type

                                             6.1.4.4 By End User

                              6.1.5  Market Share Analysis       

                                             6.1.5.1 By Geographical Area

                                             6.1.5.2 By Drug Class

                                             6.1.5.3 By Disease Type

                                             6.1.5.4 By End User

               6.2 North America                         

                              6.1.1 Introduction           

                              6.1.2 United States         

                              6.1.3 Canada     

               6.3 Europe                        

                              6.2.1 Introduction           

                              6.2.2 U.K            

                              6.2.3 Spain         

                              6.2.4 Germany  

                              6.2.5 Italy           

                              6.2.6 France      

               6.4 Asia-Pacific                

                              6.3.1 Introduction           

                              6.3.2 China        

                              6.3.3 India         

                              6.3.4 Japan        

                              6.3.5 Australia   

                              6.3.6 South Korea           

               6.5 Latin America                           

                              6.4.1 Introduction           

                              6.4.2 Brazil         

                              6.4.3 Argentina 

                              6.4.4 Mexico     

                              6.4.5 Rest of Latin America          

               6.6 Middle East & Africa              

                              6.5.1 Introduction           

                              6.5.2 Middle-East           

                              6.5.3 Africa        

7. Strategic Analysis                                      

               7.1 PESTLE analysis                        

                              7.1.1 Political    

                              7.1.2 Economic 

                              7.1.3 Social        

                              7.1.4 Technological        

                              7.1.5 Legal         

                              7.1.6 Environmental       

               7.2 Porter’s Five analysis                             

                              7.2.1 Bargaining Power of Suppliers         

                              7.2.2 Bargaining Power of Consumers     

                              7.2.3 Threat of New Entrants      

                              7.2.4 Threat of Substitute Products and Services

                              7.2.5 Competitive Rivalry within the Industry      

8. Market Leaders' Analysis                                       

               8.1 Allergan, Plc.                            

                              8.1.1 Overview 

                              8.1.2 Product Analysis   

                              8.1.3 Financial analysis  

                              8.1.4 Recent Developments        

                              8.1.5 SWOT analysis       

                              8.1.6 Analyst View          

               8.2 Abbott Laboratories (Abbott Arzneimittel GmbH)                      

               8.3 AstraZeneca Plc.                      

               8.4 Cadila Pharmaceuticals Ltd.                

               8.5 ETX Pharma, Inc                      

               8.6 Evoke Pharma                          

               8.7 GlaxoSmithKline Plc.                             

               8.8 Neurogastrx, Inc.                    

               8.9 Valeant Pharmaceuticals International, Inc.                 

               8.10 Theravance Biopharma                      

9. Competitive Landscape                                         

               9.1 Market share analysis                           

               9.2 Merger and Acquisition Analysis                       

               9.3 Agreements, collaborations and Joint Ventures                          

               9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                          

               a) List of Tables                

               b) List of Figures                             

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms product type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Gastroparesis Drugs Market, By Region, From 2021 to 2026 (USD Million)
  2. Global Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  3. Global Prokinetic Agents Market, By Region, From 2021 to 2026 (USD Million)
  4. Global Antiemetic Agents Market, By Region, From 2021 to 2026 (USD Million)
  5. Global Botulinum Toxin Injections Market, By Region, From 2021 to 2026 (USD Million)
  6. Global Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  7. Global Diabetic Gastroparesis Market, By Region, From 2021 to 2026 (USD Million)
  8. Global Idiopathic Gastroparesis Market, By Region, From 2021 to 2026 (USD Million)
  9. Global Post-surgical Gastroparesis Market, By Region, From 2021 to 2026 (USD Million)
  10. Global Others Market, By Region, From 2021 to 2026 (USD Million)
  11. Global Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  12. Global Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  13. Global Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  14. Global Clinics Market, By Region, From 2021 to 2026 (USD Million)
  15. Global E-commerce Market, By Region, From 2021 to 2026 (USD Million)
  16. North America Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  17. North America Prokinetic Agents Market, By Region, From 2021 to 2026 (USD Million)
  18. North America Antiemetic Agents Market, By Region, From 2021 to 2026 (USD Million)
  19. North America Botulinum Toxin Injections Market, By Region, From 2021 to 2026 (USD Million)
  20. North America Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  21. North America Diabetic Gastroparesis Market, By Region, From 2021 to 2026 (USD Million)
  22. North America Idiopathic Gastroparesis Market, By Region, From 2021 to 2026 (USD Million)
  23. North America Post-surgical Gastroparesis Market, By Region, From 2021 to 2026 (USD Million)
  24. North America Others Market, By Region, From 2021 to 2026 (USD Million)
  25. North America Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  26. North America Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  27. North America Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  28. North America Clinics Market, By Region, From 2021 to 2026 (USD Million)
  29. North America E-commerce Market, By Region, From 2021 to 2026 (USD Million)
  30. United States Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  31. United States Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  32. United States Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  33. Canada Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  34. Canada Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  35. Canada Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  36. Europe Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  37. Europe Prokinetic Agents Market, By Region, From 2021 to 2026 (USD Million)
  38. Europe Antiemetic Agents Market, By Region, From 2021 to 2026 (USD Million)
  39. Europe Botulinum Toxin Injections Market, By Region, From 2021 to 2026 (USD Million)
  40. Europe Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  41. Europe Diabetic Gastroparesis Market, By Region, From 2021 to 2026 (USD Million)
  42. Europe Idiopathic Gastroparesis Market, By Region, From 2021 to 2026 (USD Million)
  43. Europe Post-surgical Gastroparesis Market, By Region, From 2021 to 2026 (USD Million)
  44. Europe Others Market, By Region, From 2021 to 2026 (USD Million)
  45. Europe Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  46. Europe Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  47. Europe Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  48. Europe Clinics Market, By Region, From 2021 to 2026 (USD Million)
  49. Europe E-commerce Market, By Region, From 2021 to 2026 (USD Million)
  50. U.K. Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  51. U.K. Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  52. U.K. Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  53. Germany Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  54. Germany Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  55. Germany Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  56. France Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  57. France Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  58. France Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  59. Italy Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  60. Italy Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  61. Italy Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  62. Spain Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  63. Spain Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  64. Spain Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  65. Asia Pacific Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  66. Asia Pacific Prokinetic Agents Market, By Region, From 2021 to 2026 (USD Million)
  67. Asia Pacific Antiemetic Agents Market, By Region, From 2021 to 2026 (USD Million)
  68. Asia Pacific Botulinum Toxin Injections Market, By Region, From 2021 to 2026 (USD Million)
  69. Asia Pacific Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  70. Asia Pacific Diabetic Gastroparesis Market, By Region, From 2021 to 2026 (USD Million)
  71. Asia Pacific Idiopathic Gastroparesis Market, By Region, From 2021 to 2026 (USD Million)
  72. Asia Pacific Post-surgical Gastroparesis Market, By Region, From 2021 to 2026 (USD Million)
  73. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Million)
  74. Asia Pacific Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  75. Asia Pacific Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  76. Asia Pacific Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  77. Asia Pacific Clinics Market, By Region, From 2021 to 2026 (USD Million)
  78. Asia Pacific E-commerce Market, By Region, From 2021 to 2026 (USD Million)
  79. Japan Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  80. Japan Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  81. Japan Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  82. China Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  83. China Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  84. China Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  85. India Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  86. India Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  87. India Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  88. Australia Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  89. Australia Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  90. Australia Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  91. South Korea Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  92. South Korea Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  93. South Korea Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  94. Latin America Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  95. Latin America Prokinetic Agents Market, By Region, From 2021 to 2026 (USD Million)
  96. Latin America Antiemetic Agents Market, By Region, From 2021 to 2026 (USD Million)
  97. Latin America Botulinum Toxin Injections Market, By Region, From 2021 to 2026 (USD Million)
  98. Latin America Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  99. Latin America Diabetic Gastroparesis Market, By Region, From 2021 to 2026 (USD Million)
  100. Latin America Idiopathic Gastroparesis Market, By Region, From 2021 to 2026 (USD Million)
  101. Latin America Post-surgical Gastroparesis Market, By Region, From 2021 to 2026 (USD Million)
  102. Latin America Others Market, By Region, From 2021 to 2026 (USD Million)
  103. Latin America Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  104. Latin America Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  105. Latin America Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  106. Latin America Clinics Market, By Region, From 2021 to 2026 (USD Million)
  107. Latin America E-commerce Market, By Region, From 2021 to 2026 (USD Million)
  108. Brazil Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  109. Brazil Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  110. Brazil Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  111. Argentina Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  112. Argentina Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  113. Argentina Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  114. Mexico Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  115. Mexico Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  116. Mexico Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  117. Rest of Latin America Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  118. Rest of Latin America Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  119. Rest of Latin America Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  120. Middle East and Africa Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  121. Middle East and Africa Prokinetic Agents Market, By Region, From 2021 to 2026 (USD Million)
  122. Middle East and Africa Antiemetic Agents Market, By Region, From 2021 to 2026 (USD Million)
  123. Middle East and Africa Botulinum Toxin Injections Market, By Region, From 2021 to 2026 (USD Million)
  124. Middle East and Africa Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  125. Middle East and Africa Diabetic Gastroparesis Market, By Region, From 2021 to 2026 (USD Million)
  126. Middle East and Africa Idiopathic Gastroparesis Market, By Region, From 2021 to 2026 (USD Million)
  127. Middle East and Africa Post-surgical Gastroparesis Market, By Region, From 2021 to 2026 (USD Million)
  128. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Million)
  129. Middle East and Africa Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  130. Middle East and Africa Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  131. Middle East and Africa Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  132. Middle East and Africa Clinics Market, By Region, From 2021 to 2026 (USD Million)
  133. Middle East and Africa E-commerce Market, By Region, From 2021 to 2026 (USD Million)
  134. Middle East Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  135. Middle East Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  136. Middle East Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)
  137. Africa Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Million)
  138. Africa Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Million)
  139. Africa Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample